worth sharing

Edward Hoffer ehoffer at GMAIL.COM
Tue Aug 13 19:06:20 UTC 2019


As I have detailed in my book Prescription for Bankruptcy and in my blog
posts (https://whatswrongwithamericanhealthcare.com), conflicts of interest
are rife in American medicine.
The thought leaders, who sit on guideline panels and lecture, and the
members of FDA advisory panels, are almost all heavily in the pay of the
pharmaceutical industry.  It is a practice that must be curtailed.

Ed
Edward P Hoffer MD, FACP, FACC

On Tue, Aug 13, 2019 at 3:00 PM Samuel, Rana <
0000001850eada0c-dmarc-request at list.improvediagnosis.org> wrote:

> 2 articles that I received through 2 separate newsfeeds this week:
>
>
>
> 1) This article won an award for excellence in healthcare journalism. It
> is well worth the read:
>
>
>
>                 Reporter Heidi Ledford wrote this November story about
> how social media and patient-advisory groups have given clinical-trial
> participants unprecedented   power in how experiments are run
> <https://nature.us17.list-manage.com/track/click?u=2c6057c528fdc6f73fa196d9d&id=036dcb8393&e=d97fc80a84>
> — sometimes threatening the integrity of the research.
> <https://nature.us17.list-manage.com/track/click?u=2c6057c528fdc6f73fa196d9d&id=b06829f662&e=d97fc80a84>
> (17 min read
> <https://nature.us17.list-manage.com/track/click?u=2c6057c528fdc6f73fa196d9d&id=8b59ddb254&e=d97fc80a84>
> )
>
>
>
> 2)           Undisclosed financial conflicts of interest among authors of
> American ...
>
> *https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32408*
>
>
>
> Buried in the first (clinical trials and social media) article I found the
> following:
>
>
>
> “An evaluation of 30 patient advisory boards found that many were making
> recommendations about the convenience and feasibility of study visits, and
> the schedule of procedures performed (A. Anderson and K. A. Getz *Ther.
> Innov. Regul. Sci.* *52*, 469–473; 2018
> <https://doi.org/10.1177/2168479017720475>). The advisory boards have
> good cause to push back. Getz says that as many as one-third of
> procedures — such as blood tests or biopsies — performed during clinical
> trials are not crucial to the applications for drug approval.”
> (highlighting added my me).
>
>
>
> I have personal experience of this as well, and have reached out to have a
> lab test removed from a study protocol (evaluating post-operative rates of
> Myocardial Infarction under 2 different study conditions) because it was a
> redundant test (CK-MB) that provided no additional information over another
> test (Cardiac Troponin) that was (appropriately) included in the test
> protocol. Doing the CK-MB would have added cost to the study but provided
> no benefit, and may have resulted in harm, if the results conflicted with
> the Troponin results..
>
>
>
>                 2.  The second may help to explain the variability and
> lack of consistency among guidelines, supposedly all evidence based, that
> address the same topic (eg: ‘blood transfusion’ or ‘Cervical cancer
> screening’).
>
>
>
> Q for this group (improved Dx): I think of clinical trials and guideline
> development as highly scrutinized activities. If unnecessary tests are
> common in clinical trials, and safeguards against bias are flouted or
> watered down in groups developing guidelines, how can we expect to prevent
> unnecessary tests and bias at the (relatively unscrutinized) individual
> practitioner level?
>
>
>
> *Rana Samuel, MD, FCAP*
>
> *Chief, Pathology and Laboratory Medicine Service (PALMS, 113)*
>
> *Medical Review Officer, Federal Drug Free Workplace Program (DFWP)*
>
> VA western New York Healthcare System (VAWNYHS)
>
> 3495 Bailey Avenue, Buffalo, NY 14215
>
>
>
> *Lead pathologist* – VISN 2
>
> *Regional Commissioner*, Region 2, National Enforcement Office
>
>
>
> Ph:    716-862-8701
>
> Fax:  716-862-7824
>
> Rana.samuel at va.gov
>
>
>
> ------------------------------
>
>
> To unsubscribe from IMPROVEDX: click the following link:
>
> http://list.improvediagnosis.org/scripts/wa-IMPDIAG.exe?SUBED1=IMPROVEDX&A=1
> or send email to: IMPROVEDX-SIGNOFF-REQUEST at LIST.IMPROVEDIAGNOSIS.ORG
>
> Moderator:David Meyers, Board Member, Society for Improving Diagnosis in
> Medicine
>
> To learn more about SIDM visit:
> http://www.improvediagnosis.org/






Moderator: David Meyers, Board Member, Society to Improve Diagnosis in Medicine


HTML Version:
URL: <../attachments/20190813/3cf40e1a/attachment.html>


More information about the Test mailing list